Here’s what you should know.
1. IMM-124E showed positive effects on all levels of evaluation, including clinical parameters, tissue level parameters and immunological biomarkers.
2. Gerhard Rogler, MD, PhD, led the three stage, pre-clinical research program.
3. Researchers conducted the study in a three-stage model aimed at measuring the biological activity of IMM-124E for colitis. Dr. Rogler said the “combination of all results showed a significant and clear beneficial biological effect of IMM-124E within the model.”
4. Immuron and Dr. Rogler are moving onto the next stage of the preclinical studies.
More articles on gastroenterology:
RedHill Biopharma enrolls last patient in Bekinda phase II study: 3 notes
Olympus, Boston Scientific & more — 4 updates on GI companies
GI leader to know: Dr. John Litchfield of Palmetto Digestive Health Specialists
